Pablo Mora, MD
Diabetes America
Staff Endocrinologist
Division of Endocrinology, Diabetes and Metabolism
University of Texas Southwestern Medical Center
Plano, Texas
Diabetes America
Staff Endocrinologist
Division of Endocrinology, Diabetes and Metabolism
University of Texas Southwestern Medical Center
Plano, Texas
Related Videos
How would specific basal insulin-GLP-1 RA combination agents be used in specific patient populations with T2D? Are there trials that shed light on this?
From a clinical perspective, who are the ideal patient candidates for the fixed ratio, combination formulations, i.e. glargine insulin plus lixisenatide vs. degludec insulin plus liraglutide?
Why is the combination of basal insulin and a GLP-1 RA logical from the standpoint of mechanistic complementarity?
What is the rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How does this strategy impact pan-glycemic—FPG and PPG—control and other metabolic target goals and risk factors?
What incretin-targeted therapies are available to modulate the incretin hormones and what are the clinical differences among the available options?
What is the underlying physiology that explains the role of incretins in the disease processes leading to T2D?